ALFA Finder| Revenue growth | 15% YoY growth in Q1 FY27. |
|---|---|
| Margins | Gross margin at 50%; EBITDA margin stable at 11%. |
| Demand visibility | Strong growth in premium-value Paddy and Maize segments. |
| Management confidence | High, focused on dream-product basket and supply chain. |
Growth
Q1 Revenue at ₹3,228 Mn (+15% YoY); PAT at ₹327 Mn (+12% YoY); EBITDA margin steady at 11%.
Outlook
Strong growth in Maize (+59% value) and Paddy (+34% value) segments; maintains capacity of 25,000MT.
Risks
Seasonal demand and agri-climatic conditions; 31% increase in finance costs impacting net margins.
Last quarter's promises, checked
Delivered
- Guided 20% Cotton growth → delivered 22.35% (= BEAT)
- Guided 20-25% Paddy growth → delivered 25% (= BEAT)
- Guided 15-20% Top line growth → delivered 19% (= BEAT)
Partly delivered
- Guided EBITDA margin upward trend → delivered 12% (= PARTIAL)
Missed
- Guided 64% Gross Margin → delivered 56% (= MISS)
- Guided 11% Tax Rate → delivered 11% (= BEAT)
Investor Presentation filed with BSE, NSE: NATHBIOGEN. Summary written with AI assistance from the document.
Nath Bio-Genes (India) Ltd: key numbers
- Share price
- ₹140.13
- Market cap
- ₹266.3 Cr
- Revenue (annual)
- ₹445.1 Cr
- Net profit (annual)
- ₹41.63 Cr
- P/E (TTM)
- 7.3×Sector 29.0×
- Promoter holding
- 45.60%+0.00% QoQ
- FII holding
- 0.18%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nath Bio-Genes (India) Ltd
All →Nath Bio-Genes (India) Board Meeting Date
Nath Bio-Genes will hold a board meeting on 14 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window reopens on 17 November 2026.
Nath Bio-Genes (India) Other Announcement
Nath Bio-Genes (India) Limited filed the Compliance Certificate for the quarter ended September 30, 2026, as required under Regulation 74(5) of the SEBI regulations.
Nath Bio-Genes (India) Annual General Meeting
Nath Bio-Genes (India) Ltd held its 33rd AGM on September 24, 2026. Shareholders approved all five resolutions, including a final dividend of ₹2/- per share.
Nath Bio-Genes (India) Annual General Meeting
Nath Bio-Genes (India) Ltd issued notice for its 33rd Annual General Meeting, to be held on September 24, 2026, alongside the Annual Report for FY2025-26.
Nath Bio-Genes (India) ED Probe / Tax Survey
SEBI has initiated a forensic audit of Nath Bio-Genes (India) Ltd for financial years 2020-21 to 2025-26. CNK & Associates LLP has been appointed as the forensic auditor.
- Execution
- FY 2020-21 to 2025-26
Nath Bio-Genes (India) Q1 FY27 Results: Net Profit ₹32.3 Cr, Up 14.1% YoY
Nath Bio-Genes (India) Ltd reported revenue from operations of ₹328.4 Cr (+15.8% YoY) and net profit of ₹32.3 Cr (+14.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹32.3 Cr · +14.1% YoY